Sign In
Buy CLLS
$2.75
-0.100 (-3.51%)
At Close: Jul 31, 2026
Monthly information on share capital and company voting rights
04:30pm, Tuesday, 07'th Apr 2026
(Article 223-16 of General Regulation of the French financial markets authority) (Article 223-16 of General Regulation of the French financial markets authority)
Cellectis S.A. (CLLS) Q4 2025 Earnings Call Transcript
01:02pm, Friday, 20'th Mar 2026
Cellectis S.A. (CLLS) Q4 2025 Earnings Call Transcript
Cellectis Reports Full Year 2025 Financial Results and Provides a Business Update
07:21pm, Thursday, 19'th Mar 2026
NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to
Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026
04:30pm, Thursday, 12'th Mar 2026
NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS, NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to
Monthly information on share capital and company voting rights
04:30pm, Wednesday, 04'th Mar 2026
(Article 223-16 of General Regulation of the French financial markets authority) (Article 223-16 of General Regulation of the French financial markets authority)
Cellectis (NASDAQ:CLLS) Share Price Crosses Below 50-Day Moving Average – What’s Next?
04:12am, Saturday, 10'th Jan 2026
Shares of Cellectis S.A. (NASDAQ: CLLS - Get Free Report) passed below its 50 day moving average during trading on Friday. The stock has a 50 day moving average of $4.44 and traded as low as $4.36. Ce
Monthly information on share capital and company voting rights
04:30pm, Monday, 05'th Jan 2026
(Article 223-16 of General Regulation of the French financial markets authority) (Article 223-16 of General Regulation of the French financial markets authority)
Cellectis (NASDAQ:CLLS) Stock Crosses Above Fifty Day Moving Average – Should You Sell?
04:38am, Saturday, 20'th Dec 2025
Shares of Cellectis S.A. (NASDAQ: CLLS - Get Free Report) passed above its 50 day moving average during trading on Friday. The stock has a 50 day moving average of $4.17 and traded as high as $4.46. C
Allogene Arbitration Victory Pressures Cellectis Shares Tuesday
01:09pm, Tuesday, 16'th Dec 2025
Shares of Cellectis S.A. (NASDAQ: CLLS) tanked on Tuesday after Allogene Therapeutics Inc. (NASDAQ: ALLO) cited a favorable arbitration outcome for partner Servier in its dispute with Cellectis relate
Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis
05:39pm, Monday, 15'th Dec 2025
Arbitration Ruling Reaffirms Allogene's Full Control of Cemacabtagene Ansegedleucel (Cema-Cel) Decision Reconfirms Allogene's Expanded Sub-License Covering EU and UK Rights with Options for Japan and
Cellectis Announces Arbitral Decision in Dispute with Servier
04:51pm, Monday, 15'th Dec 2025
NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform t
Cellectis' Allogeneic CAR-T Potential Still Justifies A 'Buy'
09:31pm, Thursday, 11'th Dec 2025
CELLS develops off-the-shelf TALEN-edited CAR-T therapies. Its main in-house asset is lasme-cel for r/r B-ALL and eti-cel for r/r B-cell NHL. Early data show that lasme-cel reached impressive ORRs in
ASH 2025: Cellectis Presents Development Plan to Further Enhance High Response Rate Observed for Eti-cel in r/r NHL
01:30am, Monday, 08'th Dec 2025
NEW YORK, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform t
Monthly information on share capital and company voting rights
04:30pm, Wednesday, 03'rd Dec 2025
(Article 223-16 of General Regulation of the French financial markets authority) (Article 223-16 of General Regulation of the French financial markets authority)
NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform t
